Jenny Barnett
Co-Founder & Chief Executive Officer Monument Therapeutics
Seminars
Wednesday 16th September 2026
Panel Discussion: What Tools Can Be Used to Demonstrate Efficacy Through Early-Stage Clinical Trials? Evaluating Digital Biomarkers, EEG, PROs & Fluid Measures to Support with a Richer Analysis of Disease State
3:15 pm
- How multimodal digital biomarkers can sensitively capture early treatment signals and behavioral change before traditional clinical endpoints emerge
- The role of EEG and other neurophysiological readouts in demonstrating target engagement and pharmacodynamic effects during first in human and Phase 1/2 trials
- How structured patient reported outcomes enrich early datasets by capturing subjective symptom shifts that complement objective biomarker trends
- How fluid biomarkers – from inflammatory to neurodegenerative signatures – can provide quantifiable, mechanistic insight into early biological response and disease modulation
Wednesday 16th September 2026
MT1988: Phase 2 Insights in Identifying & Treating Cognitive Impairment in Schizophrenia
11:15 am
- Exploring digital biomarker driven stratification, based on cognitive measures, to move toward biologically homogeneous patient groups and reduce trial heterogeneity
- Investigating a fixed dose combination approach to nicotinic agonism to improve working memory and attentional deficits relevant to a range of neuropsychiatric disorders
- Advancing the first Phase 2 study to target the clinical high risk for psychosis population
- Leveraging the high profile Accelerating Medicines Partnership for Schizophrenia to identify individuals most likely to benefit from early intervention
